{
  "docId": "019de077-2e43-774b-aad6-58a03a29d59d",
  "docSlug": "207557819f8810b573d3e2a3179a9bac",
  "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 55 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 55,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "key_messages",
  "function": "present_framework",
  "density": "balanced",
  "nDataPoints": 5,
  "notes": "The slide uses a matrix-like layout to map clinical trials to patient segments. The right-hand side provides a strategic summary of the trial program's design principles.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de077-2e43-774b-aad6-58a03a29d59d/19",
  "deckHref": "/decks/019de077-2e43-774b-aad6-58a03a29d59d",
  "deckJsonHref": "/decks/019de077-2e43-774b-aad6-58a03a29d59d.json",
  "deckAnchorHref": "/decks/019de077-2e43-774b-aad6-58a03a29d59d#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.62,
        "x": 0.04,
        "y": 0.225
      },
      "kind": "diagram",
      "text": "Segmentation matrix of clinical trials by patient type (AGA, NSQ, SQ) and PD-L1 status.",
      "attrs": null,
      "subkind": "nxn-matrix",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2910342e-254a-48d2-925f-70351f569223",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.66,
        "y": 0.2
      },
      "kind": "list",
      "text": "Robust 1L programme informed by learnings from TROPION-Lung01; Building on EGFRm evidence base; Enriching for NSQ, capping SQ patients; Novel IO combinations; Prospective QCS-NMR biomarker validation",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b6819fe4-cba2-4366-9b16-da7ded4a6741",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.04,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "1. Non-risk adjusted Peak Year Revenue. Collaboration partner: Daiichi Sankyo (Dato-DXd).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2c1d8529-50aa-4d07-acbb-2f0a3d322815",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Five 1L Dato-DXd trials ongoing, representing significant share of potential $5bn+ PYR",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e64e27d2-582e-48d0-839a-b48e7a69a613",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "NxN matrix",
      "slug": "matrix-nxn",
      "agent": null,
      "layer": "slide",
      "matchId": "e8210b4a-105c-4240-b53c-806e3fbeac13",
      "evidence": "diagram/nxn-matrix: Segmentation matrix of clinical trials by patient type (AGA, NSQ, SQ) and PD-L1 status.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "matrix-nxn",
      "slug": null,
      "matchId": "2b8fcc8f-1bd7-4140-b006-eb4841571777",
      "evidence": "The slide organizes clinical trials into a grid based on patient segments (AGA, NSQ, SQ) and PD-L1 status.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}